Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb;53(3):443-444.
doi: 10.1111/apt.16191.

Editorial: vedolizumab in inflammatory bowel diseases-less is more?

Tristan Townsend  1 , Sreedhar Subramanian  1
Affiliations
Editorial

Editorial: vedolizumab in inflammatory bowel diseases-less is more?

Tristan Townsend et al. Aliment Pharmacol Ther. 2021 Feb.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Danese S, Subramaniam K, Van Zyl J, et al. Vedolizumab treatment persistence and safety in a 2-year data analysis of extended access programme. Aliment Pharmacol Ther. 2020;53:265-272.
    1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
    1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
    1. Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and α4β7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:697-705.e7.
    1. Vermeire S, Lukáš M, Magro F, et al. Vedolizumab efficacy, safety, and pharmacokinetics with reduced frequency of dosing from every 4 weeks to every 8 weeks in patients with Crohn's disease or ulcerative colitis. J Crohns Colitis. 2020;14:1066-1073.

MeSH terms

Substances